Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study코로나바이러스 질병-2019에 대한 치료용 혈장 교환은 사이토카인 방출 증후군을 유발했습니다. 후향적 성향 일치 대조 연구Research Article Published on 2021-01-072022-08-13 Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, [키워드] 1:1 95% CI Analysis analyzed assigned both groups Cohort Control controls coronavirus coronavirus disease coronavirus disease-2019 COVID-19 Critical CRS cytokine cytokine release Cytokine release syndrome Cytokines discharge disease severity duration of hospitalization evaluate Forced groups hospital hospitalized patient in both group log rank male males median age moderate Mortality non-randomized objective outcome pathogenic pathophysiology Patient plasma plasma exchange polymerase chain reaction Polymerase chain reaction testing Primary outcome progression PSM reduced Result retrospective secondary Secondary outcomes selected severity significantly standard care Standard of care supportive care survival Symptom syndrome the patient Therapeutic plasma exchange TPE treated Treatment triggered Viral viral clearance was done was used with COVID-19 [DOI] 10.1371/journal.pone.0244853 PMC 바로가기 [Article Type] Research Article
Rehabilitation Exercise and psycholoGical support After covid-19 InfectioN’ (REGAIN): a structured summary of a study protocol for a randomised controlled trial재활 운동 및 심리적 지원 After covid-19 Infection'(REGAIN): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-01-062022-09-10 Journal: Trials [Category] MERS, 임상, [키워드] 1:1 age allocation concealment anticipated anxiety symptoms assessment automatically baseline Bengali best blind Blinding Care clinical clinically Cognitive function Complete computer-generated Controlled trial COVID-19 COVID-19 infection Critical care current death defined depressive determine dissemination Dyspnoea eight element email engage Engagement English exclusion criteria exercise Group allocation Health health economic evaluation health problems hospital hospital care hospital discharge include Informed consent life mental health mental health problem mental health problems NHS number objective Online outcome parallel group participant performed physical physical activity Physical health Post-traumatic stress disorder Practitioner Primary outcome profile protocol psychological support PTSD Quality of life questionnaire randomisation randomised randomised controlled trial rehabilitation Rehabilitation Exercise reported resource Sample size secondary Secondary outcomes sequence Standard status stratified Study protocol Support supported symptom severity Treatment Urdu usual care utility ventilatory ventilatory support Version web-based system website [DOI] 10.1186/s13063-020-04978-9 PMC 바로가기 [Article Type] Letter
A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)Letter Published on 2021-01-062022-08-31 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] 1:1 administration age allergic Analysis appearance Arm ARMS assumed Asymptomatic balancing Blinding body temperature calculated capture cardiovascular disease Chain Reaction clinical clinical trials cloud condition Control control group cough COVID-19 diabetes disappearance dissemination doctor dosage dropout rate drug edema effective element Endpoint exclusion criteria failure Fever Final final analysis final analysis) Frequency group hands healthy history hospital Hospitalization hypertension hypokalaemia Hypothesis ICU Immunosuppressant immunosuppressants incidence of COVID-19 incidence rate incidence rates include inclusion criteria Infection infection rate Inflammation interim analysis interstitial pneumonia intervention group investigator Japan Japanese Kampo Kampo medicines liver dysfunction lung malaise management mechanical ventilation Medicine number numbness objective observation period oral administration oral administration) outcome package parallel-group participant Patient PCR PCR positive per day Period pharmaceutical Placebo placebo group Placebo tablets positive result power power of 80% pregnant Prevent Prophylactic prophylactic study protocol randomised Randomized Randomized controlled trial RCT receive recruited Registered Registration registry required Research respiratory respiratory diseases respiratory inflammation risk factor Risk factors Safety Sample size SARS-CoV-2 RNA secondary Secondary outcomes Shock Shortness of breath significantly skin rash sputum study drug study period Study protocol supplementary material Symptom Symptoms symptoms of COVID-19 Tablet Taking Taste the placebo group Trial Trial registration Two-arm university upper respiratory verification Viral viral infection Vital website [DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)Letter Published on 2021-01-042022-09-10 Journal: Trials [Category] 임상, [키워드] 24 hour 24 hours Activation activities acute lung injury addition adjusted Administered administration allergy Antibiotics anticipated anticoagulation arterial Arterial hypertension Basel Blinding BMI Brazil Breast Breast feeding breathing ambient air C-reactive protein C1 esterase inhibitor cardiovascular disease Caregivers changes in Chest Child-Pugh score chronic chronic pulmonary disease chronic renal disease cirrhosis class clinical Clinical improvement clinical trial comparator comparator Patients complement complement system completion conducted Conestat alfa Contact contact activation system contraindication control group Corticosteroids COVID-19 COVID-19 patient CT scan death defined discharge disease disease severity dissemination drug Duration Efficacy and safety element eligibility enrolment evidence of experimental arm family members FIVE followed by history hospital Hospitalization hospitalized patient hypertension ICU IL-6 inhibitor IL-6R improvement Incapacity include inclusion criteria individual Infection inflammatory cascade inflammatory cascades inflammatory proteins inhibitor Interactive Web Response System interim analysis Intravenous injection invasive invasive or non-invasive ventilation investigator-initiated investigators kallikrein kinin system laboratory parameter Liver cirrhosis Local Lung injury mechanical ventilation non-invasive ventilation not blinded number obesity objective Open-label open-label trial Ordinal Scale outcome outcome assessor outcome assessors oxygen oxygen saturation pandemic PaO parallel-group participant Participants Participation Patient performed Pregnancy primary endpoint progression proportion protocol pulmonary disease pulmonary involvement randomised randomization Randomized randomized trial receive recombinant recruited recruitment Registered Remdesivir renal renal disease required risk factor Sample size SARS-COV-2 infection SARS-CoV-2 pandemic scale screened secondary Secondary outcomes severe COVID-19 severe SARS-CoV-2 Standard of care status Study protocol subject supplemental oxygen supplementary material suspicion Switzerland Symptom the SARS-CoV-2 the WHO their family members Tocilizumab Treatment treatment arm Trial Two interim analyses Two interim analysis virological clearance website WHO WHO ordinal scale with COVID-19 X-ray [DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trialCOVID-19 치료를 위한 아르테미시닌-피페라퀸의 안전성 및 효능: 공개, 비무작위 및 대조 시험Controlled Clinical Trial Published on 2021-01-012022-09-11 Journal: International journal of antimicrobial agents [Category] SARS, 임상, 치료법, 치료제, [키워드] 95% CI 95% confidence interval adverse events antimalarial Artemisinin both groups change changes Computed tomography control group Controlled trial coronavirus coronavirus disease coronavirus disease-2019 COVID-19 effective therapy Efficacy enrolled group laboratory parameter Mean ± standard deviation Mild Mild-to-moderate Open-label participant Patient percentage percentages physician Piperaquine Primary outcome QT interval respiratory Safety SARS-CoV-2 Secondary outcomes Severe acute respiratory syndrome severe acute respiratory syndrome-coronavirus-2 significantly shorter Standard deviation Treatment two groups undetectable Viral Viral RNA [DOI] 10.1016/j.ijantimicag.2020.106216 PMC 바로가기 [Article Type] Controlled Clinical Trial
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical TrialCOVID-19 및 중등도 또는 중증 폐렴으로 입원한 성인에서 Tocilizumab 대 일반 치료의 효과: 무작위 임상 시험Randomized Controlled Trial Published on 2021-01-012022-09-11 Journal: JAMA Internal Medicine [Category] 임상, 진단, 치료제, [키워드] 95% CI adjusted Admission adverse event adverse events age Analysis antibiotic Anticoagulants Antiviral agents ARD assigned Bayesian C-reactive protein Care clinical clinical status clinical trial clinically conducted Consent coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 pneumonia credible interval CrI death determine did not reduce died discharge Effect Efficacy elevated Factor Fewer patients Follow-up France greater hazard ratio Health Organization hyperinflammation Identifier IMPROVE indicated intensive care intensive care unit intention-to-treat basis interleukin-6 interquartile range intravenously investigator-initiated less mechanical ventilation median moderate moderate-to-severe COVID-19 pneumonia Mortality multicenter multiplicity NIV no difference Noninvasive ventilation occurred Open-label outcome overall survival oxygen oxygen supply oxygen support Patient patients patients hospitalized patients with COVID-19 performed Pneumonia posterior probability Primary outcomes randomized clinical trial Randomly receive recruited reduced risk risk difference scale secondary Secondary outcomes Serious Adverse Events severe pneumonia survival TCZ threshold Tocilizumab treat university hospital usual care usual care alone vasopressor support Ventilation WHO-CPS women World Health Organization [DOI] 10.1001/jamainternmed.2020.6820 PMC 바로가기 [Article Type] Randomized Controlled Trial
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical TrialOriginal Article Published on 2021-01-012022-10-30 Journal: Iranian Journal of Pharmaceutical Research : IJPR [Category] COVID-19, [키워드] Admission Adverse reaction analyzed assigned Atazanavir clinical Clinical outcome clinical recovery clinical trial Coronavirus disease 2019 COVID-19 discharged double-blind Efficacy Efficacy and safety enrolled Frequency groups HCQ Hospital stay Hydroxychloroquine ICU ICU admission intensive care Intervention Intubated intubation Lopinavir Lopinavir/ritonavir median moderate Mortality nausea participant patients Primary outcome Randomized Randomly receive reduced reported Safety Secondary outcomes single dose statistically vomiting [DOI] 10.22037/ijpr.2021.115157.15243 PMC 바로가기 [Article Type] Original Article
Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in ItalyClinical Trial Published on 2021-01-012022-10-05 Journal: Journal of clinical lipidology [Category] SARS, 임상, [키워드] 95% CI Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Admission Affect Anti-inflammatory association clinical condition Clinical outcome cohorts Comorbidities Comorbidity complications consecutive patient coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 pandemic COVID-19 prognosis enrolled Evidence favorable effect Hospitalized immunomodulatory property Impact in-hospital mortality increased risk intensive care Italy Logistic regression analysis mechanical ventilation Mortality mortality rates multicenter Noninvasive ventilation outcomes Patient Propensity score reduce respiratory syndrome coronavirus risk of infection score Secondary outcomes severe COVID-19 severe disease severity severity of COVID-19 statin Statin therapy. tertiary referral hospital therapy treated was used [DOI] 10.1016/j.jacl.2020.12.008 PMC 바로가기 [Article Type] Clinical Trial
Randomised placebo-controlled multicentre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community-acquired pneumonia: a trial protocol for the KIDS-STEP trial지역사회획득 폐렴으로 입원한 소아에 대한 보조 베타메타손 요법의 무작위 위약 대조 다기관 유효성 시험: KIDS-STEP 시험을 위한 시험 프로토콜Article Published on 2020-12-292022-09-11 Journal: BMJ Open [Category] SARS, 임상, [키워드] 48 hour 48 hours ACCIDENT & addition Adults Ambulatory care analysed and ambulatory care antibiotic approved average betamethasone Caregivers cause children clinically community-acquired pneumonia Complication double-blind E Each Effectiveness Emergency Departments emergency medicine enrolled Ethics Evidence healthcare hospital Hospital stay hospitalisation hospitalised immunisation include increase in Infectious disease inferiority Informed consent International lack margin matching placebo media multicentre National non-inferiority observational studies outcome paediatric A& paediatric infectious disease & paediatric thoracic medicine. participant Patient peer-reviewed Placebo placebo-controlled Pneumonia power power of 80% press proportion randomisation randomised readmission registration number regulatory authority Sample size secondary Secondary outcomes social media stability Standard of care steroid steroid treatment Steroids Swissmedic Switzerland therapy Thoracic Treatment Trial trial protocol use of steroids [DOI] 10.1136/bmjopen-2020-041937 PMC 바로가기 [Article Type] Article
COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial고위험 고령 환자를 대상으로 한 COvid-19 및 고용량 비타민 D 보충제 TRIAL(COVIT-TRIAL): 무작위 대조 시험을 위한 연구 프로토콜Randomized Controlled Trial Published on 2020-12-282022-08-13 Journal: Trials [Category] MERS, SARS, 신약개발, 임상, [키워드] albumin all-cause mortality Anti-inflammatory Antiviral assumption baseline calcium change Chemoprevention chest CT scan cholecalciferol clinical Concentration contraindication COVID-19 COVID-19 pandemic creatinine diagnosed drug effective effective therapy epidemiological expected FiO2 first randomized controlled trial Health Organization High dose High-dose higher risk Hope human cell human cells IMPROVE improvement incidence Inclusion increase Infection knowledge lack mortality rate multicenter Observational data Older Older adults older patient older patients Open-label Ordinal Scale outcome PaO2 paO2/fiO2 participant primary outcome measure Prognosis Randomized Randomized controlled trial recruited risk factor room air RT-PCR SARS-CoV-2 scale secondary Secondary outcomes serum serum concentrations SpO2 Standard dose Standard-dose Study protocol Support target the SARS-CoV-2 treatment for COVID-19 Trial Trial registration vaccination Vitamin D Vitamin D supplementation with COVID-19 World Health Organization worsening [DOI] 10.1186/s13063-020-04928-5 PMC 바로가기 [Article Type] Randomized Controlled Trial